[Comment] Obicetrapib–ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with atherosclerotic cardiovascular disease (ASCVD) contributing substantially to this burden.1,2 Given the well-established association between LDL cholesterol and the risk of developing ASCVD, reducing LDL cholesterol concentrations represents a cornerstone for management of patients with ASCVD or populations at elevated risk, including those with heterozygous familial hypercholesterolaemia (HeFH). The 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on lipid management classify those with ASCVD as a very high-risk population and strongly recommend that these patients reach at least a 50% reduction from their baseline LDL cholesterol concentration while maintaining levels below 55 mg/dL.